Eli Lilly and Company (NEO:LLY)

Canada flag Canada · Delayed Price · Currency is CAD
28.12
-0.13 (-0.46%)
Jun 5, 2025, 9:30 AM EDT
-10.25%
Market Cap 924.74B
Revenue (ttm) 70.43B
Net Income (ttm) 15.96B
Shares Out n/a
EPS (ttm) 17.66
PE Ratio 57.93
Forward PE 29.99
Dividend n/a
Ex-Dividend Date n/a
Volume 33,212
Average Volume 54,609
Open 28.44
Previous Close 28.25
Day's Range 27.75 - 28.44
52-Week Range 25.15 - 36.42
Beta 0.39
RSI 51.40
Earnings Date Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange Cboe Canada
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

There is no news available yet.